Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Immunology Right
  3. Taltz (ixekizumab) injection Right
  4. What is the mechanism of action of Taltz® (ixekizumab) in axial spondyloarthritis?
Search Taltz (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Taltz ® (ixekizumab) injection

80 mg/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the mechanism of action of Taltz® (ixekizumab) in axial spondyloarthritis?

Information on the mechanism of action of ixekizumab in axial spondyloarthritis is available in this response.

US_cFAQ_IXE011_MECHANISM_OF_ACTION_axSpA
US_cFAQ_IXE011_MECHANISM_OF_ACTION_axSpA
en-US

Role of Interluekin-17A

Interleukin-17A (IL-17A) is a pleiotropic cytokine that is involved in inflammatory functions and host protection against specific pathogens, and is important in inducing specific chemokines (eg, interleukin 8 and C-C motif chemokine ligand 20) that recruit leukocytes such as neutrophils. Several cell types have been shown to produce IL-17, including, but not limited to

  • T cells
  • innate lymphoid cells
  • granulocytes, and
  • macrophages.1-3

Interleukin-17A is an important cytokine involved in the immunopathology of axial spondyloarthritis, including

  • inflammation 
  • bone erosion
  • dysregulated bone formation
  • enthesitis, and
  • synovitis.4

Ixekizumab Impact on IL-17A

Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody that selectively binds with the IL-17A cytokine and inhibits its interaction with its receptor. Disruption of IL-17 binding to its receptor inhibits the release of proinflammatory effectors, including cytokines and chemokines which in turn can result in a reduction or inhibition of the inflammatory pathogenic mechanisms described above.1-3

Ixekizumab selectively binds to IL-17A. Ixekizumab was engineered to have an amino acid point mutation in the hinge region to prevent the formation of half antibodies, and thus reduce antibody heterogeneity.5

Enclosed Prescribing Information

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Mease P, Lubberts E, McInnes I, van der Heijde D. IL-17 inhibition in spondyloarthritis: a targeted approach in psoriatic arthritis. EMJ Rheumatol. 2015;2(1):55-64. https://www.emjreviews.com/rheumatology/symposium/il-17-inhibition-in-spondyloarthritis-a-targeted-approach-in-psoriatic-arthritis

2Mease PJ, van der Heijde D, Ritchlin CT, et al; SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79-87. http://dx.doi.org/10.1136/annrheumdis-2016-209709

3Nash P, Kirkham B, Okada M, et al; SPIRIT-P2 Study Group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317-2327. http://dx.doi.org/10.1016/S0140-6736(17)31429-0

4Raychaudhuri SK, Saxena A, Raychaudhuri SP. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol. 2015;34(6):1019-1023. http://dx.doi.org/10.1007/s10067-015-2961-7

5Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39-50. http://dx.doi.org/10.2147/JIR.S100940

Date of Last Review: March 03, 2023

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly